MIAMI / Sep 24, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC MIAMI / Sep 24, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that... Read More

With Longer-Term Follow-Up of Western Patients, Ivonescimab Plus Chemotherapy Demonstrated Improving Global OS Trend with Nominal p-value of 0.0332 vs. Chemotherapy Alone; North American Patients’ OS HR=0.70 Consistent Median Overall Survival Observed in Western, Asian Patients in Longer-Term Follow-Up Analysis of Western Patients Presented at Presidential Symposium at WCLC 2025 Conference Call to be Held at 8:00am ET on... Read More

Leadership to Discuss Full Presentation Data from HARMONi, the Global Phase III Clinical Trial Featured in the Presidential Symposium at WCLC 2025 MIAMI / Sep 03, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, HARMONi, presented as part of the Presidential Symposium at the... Read More

Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year MIAMI / Aug 14, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the... Read More

Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to... Read More

MIAMI / Jun 06, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

MIAMI / Jun 05, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 46 th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the... Read More

Consistent Results Noted between Single Region HARMONi-A and Multiregional HARMONi Studies; Favorable Trends in Sub-Populations from North America and China for Both Primary Endpoints Were Observed Ivonescimab in Combination with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone; Positive Overall Survival Trend Observed with Hazard Ratio of 0.79 HARMONi Represents the First... Read More

MIAMI / May 16, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 94,050 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as... Read More

Interim Analysis of HARMONi-2 Shows an Overall Survival Hazard Ratio of 0.777 Favoring Ivonescimab at 39% Data Maturity, Implying a Potential Numerical 22% Reduction in the Risk of Death Compared to Pembrolizumab Ivonescimab Monotherapy Approved by NMPA in China for Front-Line PD-L1 Positive Advanced NSCLC MIAMI / Apr 25, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today... Read More

Conference Call to be Held at 4:30pm ET MIAMI / Apr 24, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be... Read More

Ivonescimab in Combination with Chemotherapy in the HARMONi-6 Study Conducted by Akeso Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC PFS Improvement Was Observed across Tumors with PD-L1 Negative and PD-L1 Positive Expression in the HARMONi-6 Clinical Trial Conducted by Akeso Full Data Set to be... Read More

MIAMI / Apr 04, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

MIAMI / Mar 21, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry MIAMI / Mar 17, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W.... Read More

MIAMI / Mar 14, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 122,650 shares of common stock. Awards were made to 12 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

Clinical Trial Collaboration with Pfizer Evaluating Ivonescimab in Combination with Several Vedotin ADCs in Unique Solid Tumor Settings; Clinical Trials Expected to Start Mid-2025 Enrollment Completed for Global, Multi-Regional Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Top-Line Data Expected Mid-2025; Received Fast Track Designation from FDA HARMONi-3 Global Phase III Trial Expanded to Include Patients with... Read More

Summit and Pfizer Seek to Accelerate Development Opportunities of Ivonescimab and Vedotin-based ADCs Pfizer to Contribute Multiple ADCs to Evaluate with Ivonescimab in Unique Solid Tumor Settings Clinical Trials Expected to Start in the Middle of This Year MIAMI / Feb 24, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate... Read More

Conference Call to be Held at 9:00am ET MIAMI / Feb 18, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial results and provide an operational update for the Company on Monday, February 24, 2025, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am... Read More

MIAMI / Feb 14, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

MIAMI / Jan 16, 2025 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

MIAMI / Dec 13, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

MIAMI / Nov 26, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7 th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovative investigational bispecific... Read More

MIAMI / Nov 21, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC in China Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data... Read More

Conference Call to be Held at 9:00am ET MIAMI / Oct 23, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which... Read More

MIAMI / Oct 04, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 249,550 shares of common stock. Awards were made to ten new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC HARMONi Completed Enrollment for Summit’s First Sponsored Study Evaluating Ivonescimab Topline data from the HARMONi Trial Is Expected in Mid-2025 MIAMI / Oct 03, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional... Read More

Two Oral Presentations Featured Updated Ivonescimab Data from Phase II Studies in CRC and TNBC in Addition to Poster Presentation on HNSCC Encouraging Phase II Data Supports the Continuing Expansion of the Clinical Development of Ivonescimab Outside of Metastatic Non-Small Cell Lung Cancer MIAMI / Sep 16, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that... Read More

Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at Yesterday’s Closing Price of $22.70 MIAMI / Sep 12, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of... Read More

Summit to Initiate HARMONi-7, a Phase III Trial in First-Line PD-L1 High, Advanced NSCLC, in Early 2025 Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC Median PFS of 11.14 Months vs. 5.82 Months, Respectively, for Patients Receiving Ivonescimab vs. Pembrolizumab; PFS Improvement Was Observed Broadly in Patients Across Subgroups,... Read More

MIAMI / Sep 06, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 102,000 shares of common stock. Awards were made to five new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit Compared to Monotherapy Pembrolizumab in HARMONi-2 Trial Conducted by Akeso Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC Additionally, Ivonescimab Phase II Data in Perioperative Setting for Resectable NSCLC to be Presented MIAMI / Aug 12, 2024 / Business Wire / Summit... Read More

First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG , Aug. 11, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the... Read More

MIAMI / Aug 09, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 453,250 shares of common stock. Awards were made to fourteen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with... Read More

Ivonescimab Monotherapy Achieved Statistically Significant & Clinically Meaningful Improvement over Pembrolizumab Monotherapy Head-to-Head in HARMONi-2 Phase III Trial in 1L Advanced NSCLC Positive HARMONi-A Data Featured at ASCO and Published in JAMA Supporting Ivonescimab's First Regulatory Approval in China for 2L+ EGFRm Advanced NSCLC HARMONi and HARMONi-3 Enrollment Continues with HARMONi Planned to Complete Enrollment... Read More

Conference Call to be Held at 9:00am ET MIAMI / Jul 29, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2024 financial results and provide an operational update for the Company on Tuesday, August 6, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will... Read More

Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials MIAMI & HOUSTON / Jul 25, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of... Read More

MIAMI / Jul 03, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq... Read More

MIAMI / Jun 27, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. “It is an honor to add Jeff Huber to our excellent, diverse group of board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “Jeff’s executive leadership experience in healthcare... Read More

$200 Million in Net Proceeds Raised at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa Expansion Is in Addition to Existing License Territories of US, Canada, Europe, and Japan Conference Call to be Held at 8:00am ET on Monday, June 3, 2024 MIAMI / Jun 03, 2024 / Business Wire / Summit... Read More

Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024 Conference Call to be Held at 8:00am ET on Monday, June 3, 2024 MIAMI / Jun 01, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American... Read More

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3 rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab due to Adverse Events vs. 2.5% Treatment Discontinuation of Placebo HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31,... Read More

MIAMI / May 30, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 200,000 shares of common stock. An award was made to one new employee of the Company. The award was granted as an inducement material to the new employee becoming an employee of the Company in accordance with Nasdaq... Read More

Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies Full Data... Read More

HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSCLC Patients with Brain Metastases Board of Directors Strengthened with the Addition of Dr. Mostafa Ronaghi Updated Guidance of Cash Runway... Read More

Conference Call to be Held at 9:00am ET MIAMI / Apr 24, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be... Read More

MIAMI / Apr 11, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. “Mostafa has valuable experience... Read More

MIAMI / Apr 10, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief... Read More

Ivonescimab alone or combined with chemotherapy led to intracranial responses among 34% of patients with brain metastases at baseline – 23% achieved a complete response All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO criteria irrespective of cohort Median intracranial PFS of 19.3 months observed across combined cohorts of ivonescimab administered as monotherapy... Read More

Two Poster Presentations Will Feature Updated Ivonescimab Data from the AK112-201 and AK112-202 Phase II Studies in Advanced or Metastatic NSCLC Patient Populations Posters to be Presented by Dr. Li Zhang and Dr. Jack West on Friday, March 22 in Prague MIAMI / Mar 14, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential... Read More

MIAMI / Mar 05, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26 th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on... Read More

Actively Enrolling Two Phase III Clinical Studies in NSCLC for Ivonescimab: HARMONi and HARMONi-3 Updated Phase II Data Announced for Ivonescimab Highlighting 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients and mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients SITC 2023 Poster Presentation Featured Novel Cooperative Binding Characteristics of Ivonescimab, Enabling Higher Affinity and Avidity in the Tumor... Read More

Financial Results & Operational Progress Call on February 20, 2024 Conference Call to be Held at 9:00am ET MIAMI, Fla. / Feb 14, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financial results and provide an operational update for the Company on Tuesday, February 20, 2024, before the market opens.... Read More

MIAMI / Feb 07, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer’s 34 th Annual Healthcare Life Sciences Conference, which will be held virtually. Summit will present on Wednesday, February 14, 2024, at 2:40PM ET. Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and... Read More

Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating Ivonescimab in China Conducted by Akeso, including Head-to-Head vs. Pembrolizumab MIAMI / Jan 08, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today... Read More

MENLO PARK, Calif. / Jan 03, 2024 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executive Officer and President, will provide details around... Read More

Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3 Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024 Manmeet S. Soni Joined Summit as COO, Invested $5 Million in the Company Dave Gancarz, Dr. Urte Gayko, Dr. Fong Clow, & Dr. Allen S. Yang Elevated to Leadership Positions Dr. Jack West & Dr. Laura Chow Bolster Summit's Clinical... Read More

Dr. Chow Brings Two Decades of Immunotherapy & Anti-Angiogenic Cancer Treatment Experience to Team Summit MENLO PARK, Calif. / Nov 02, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development. “Dr. Chow has spent her career working on the development of immunotherapies... Read More

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of SMT112 Enables Higher Avidity in the Tumor Microenvironment with Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in vitro MENLO PARK, Calif. / Oct 31, 2023 / Business Wire / Summit Therapeutics Inc . (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”)... Read More

Conference Call to Be Held at 9:00am ET MENLO PARK, Calif. / Oct 26, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company on Tuesday, November 7, 2023, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am... Read More

Dr. West Brings over 25 Years of Trusted Clinical Expertise in Thoracic Oncology MENLO PARK, Calif. / Oct 19, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Howard “Jack” West, MD, has joined Summit Therapeutics as Vice President of Clinical Development focused on lung cancer. “Dr. West brings a wealth of experience, and his knowledge in treating lung... Read More

Mr. Soni Invests $5 Million in Summit while Joining Executive Team In Corresponding Appointments, Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, & Allen S. Yang, MD, PhD, Elevated to Newly Established Leadership Roles MENLO PARK, Calif. / Oct 16, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief... Read More

Promising Updated Phase II Data Presented at ASCO 2023 for Ivonescimab First US Patient Treated in Ivonescimab Phase III Clinical Trial with the First Patient in Ivonescimab's Second Phase III Clinical Trial Planned for the Second Half of 2023 MENLO PARK, Calif. / Aug 09, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an... Read More

Conference Call to be Held at 9:00am ET MENLO PARK, Calif. / Aug 02, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2023 financial results and provide an operational update for the Company on Wednesday, August 9, 2023, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am... Read More

Data Supporting Summit’s Planned Phase III Trial for First-line Metastatic Squamous NSCLC Patients on Display Phase II ORR of 67% with a mDOR of 15 months in 1L SQ-NSCLC Patients MENLO PARK, Calif. / Jun 04, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab,... Read More

Summit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab MENLO PARK, Calif. / Jun 01, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American... Read More

First US Patient Treated in Ivonescimab Clinical Trial after Closing Agreement; $500M Raised in Fully-Subscribed Rights Offering MENLO PARK, Calif. / May 11, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the first quarter ended March 31, 2023. Operational & Corporate Updates Our... Read More

Phase III Study Designed to Establish the Effect of Ivonescimab in Lung Cancer Patients Whose Tumors Progressed after EGFR-TKI Therapy MENLO PARK, Calif. / May 09, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized,... Read More

Studies Designed in Alignment with Feedback from FDA Company to Host Q1 Earnings Call on May 11, 2023 at 9:00am ET MENLO PARK, Calif. / May 03, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential... Read More

MENLO PARK, Calif. / Mar 09, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December 31, 2022. Operational & Corporate Updates Our Collaboration and License Agreement with Akeso Inc. ("Akeso") for ivonescimab: On December 5, 2022, Summit and Akeso entered... Read More

MENLO PARK, Calif. / Mar 03, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the successful closing of its fully-subscribed $500 million rights offering. The rights offering resulted in the sale of approximately 476.2 million shares of the Company’s common stock, par value $0.01, at a price of $1.05 per share. The Company received aggregate gross proceeds from... Read More

MENLO PARK, Calif. / Feb 23, 2023 / Business Wire / Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the “Expiration Date”). As a reminder, the subscription price per share shall be equal to the lesser of (i) $1.05 per share or (ii) the volume weighted-average... Read More

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”) to in-license its breakthrough bispecific antibody, ivonescimab. Ivonescimab, known as AK112 in China and Australia, and as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential... Read More

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 09, 2023, at 3:45 PM PST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Co-Chief Executive Officer and President, will provide details regarding our Company following the announcement of our... Read More

Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies. The... Read More